Telix Presents Encouraging Phase 3 Results for TLX591-Tx at ASCO 2026
MELBOURNE, Australia & INDIANAPOLIS, U.S., June 2, 2026 Telix Pharmaceuticals announced positive Part 1 data from its global Phase...
mCRPC
Advertisement
Convergent’s CONV01-α Shows Promising Activity in Post-Lu-PSMA Prostate Cancer Phase 2 Study
CAMBRIDGE, Mass., June 2, 2026 Convergent Therapeutics announced positive interim Phase 2 data from its CONVERGE-01 study evaluating CONV01-α...
Foundation Medicine Gains FDA Approval for TALZENNA CDx
BOSTON, June 1, 2026 Foundation Medicine announced that the U.S. Food and Drug Administration (FDA) has approved both FoundationOne®...
Haisco and Lilly Forge $3B Deal to Advance New Medicines
SILICON VALLEY, Calif. & BEIJING, June 1, 2026 Haisco Pharmaceutical Group Co., Ltd. has announced a landmark licensing and...
Curium Invests €32M to Expand Prostate Cancer RLT Production
PARIS, France, June 1, 2026 Curium, a global leader in radiopharmaceuticals and nuclear medicine, has announced a strategic investment...
Advertisements
Aktis Oncology Starts Phase 1b Trial for AKY-2519
BOSTON, May 04, 2026 Aktis Oncology has announced the initiation of a Phase 1b clinical trial evaluating AKY-2519, a...
Telix Advances TLX597-Tx Phase 2 Prostate Cancer Program
MELBOURNE, Australia & INDIANAPOLIS, IN, April 30, 2026 Telix Pharmaceuticals has announced encouraging dosimetry results from its Phase 2...
Janux Therapeutics Doses First Patient in JANX014 Study
SAN DIEGO, USA, April 16, 2026 Janux Therapeutics, Inc. has announced a key clinical milestone with the first participant...
Pasritamig Shows Strong Phase 1b Results in mCRPC
RARITAN, N.J., February 26, 2026 Johnson & Johnson announced encouraging preliminary results from a Phase 1b clinical study evaluating...
J&J Pasritamig Combo Shows Strong mCRPC Activity
RARITAN, N.J., February 26, 2026 Johnson & Johnson (NYSE: JNJ) announced preliminary Phase 1b clinical results demonstrating promising antitumor...
Advertisement
